期刊文献+

激素联合环磷酰胺治疗ANCA相关性血管炎合并肾损害的临床研究 被引量:4

下载PDF
导出
摘要 目的研究激素联合环磷酰胺(CTX)对ANCA相关性血管炎(AAV)合并肾损害患者的治疗效果。方法分析使用激素联合环磷酰胺治疗AAV合并肾损害的45例患者资料,以及单用激素治疗的21例患者资料,比较2组患者治疗前、治疗后1周及1个月的临床资料与实验室检查。结果治疗1周后2组患者伯明翰血管炎活动评分(BVAS)、24h尿蛋白定量、Scr、CRP下降的比例,差异无统计学意义(P>0.05);治疗1个月后联合治疗组以上指标的改善均较单用激素治疗患者明显,差异有统计学意义(P<0.05)。结论激素联合环磷酰胺对控制ANCA相关性血管炎患者病情活动及缓解肾脏损害有着良好的临床效果。
出处 《临床合理用药杂志》 2013年第29期56-57,共2页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献7

  • 1Chen M, Kallenberg CG. New advances in the pathogenesis of ANCA as- sociated vasculitides [ J ]. Clin Exp Rheumatol, 2009,27 ( 1 ) : S108 - S114. 被引量:1
  • 2Jennette JC, Falk R J, Andrassy K,et al. Nomenclature of systemic vascu-[irides. Proposal of an international consensus conference [ J ]. Arthritis Rheum,1994,37(2) :187 - 192. 被引量:1
  • 3Luqmani RA, Bacon PA, Mools RJ, et al. Birmingham vasculitis activity score ( BVAS ) in systemic necrotizing vasculitis [ J ]. Q J Med, 1994,87 : 671 -678. 被引量:1
  • 4Harper L,Savage CO. ANCA-asseciated renal vasculitis at the end of the twentieth centry-a disease of older patients[ J]. Rheumatology( Oxford), 2005,55:495 - 450. 被引量:1
  • 5Little MA, Nazar L, Farrlngton K. Outcome in glomerulonephritis due to systemic small vessel vasculitis: Effect of functional status and non-vas- culitic co-morbidity [ J ]. Nephrol Dial Transplant, 2004,19 : 356 - 364. 被引量:1
  • 6Xiao H, Heeringa P, Hu P. Antineutrophil cytoplasmic autoantibodies specific for mycloperoxidase cause glome~donephritis and vasculitis in mice [ J ]. J Clin Invest,2002,110:995 - 963. 被引量:1
  • 7胡伟新,刘春蓓,谢红浪,王庆文,陈惠萍,刘志红,黎磊石.霉酚酸酯与环磷酰胺治疗ANCA相关血管炎的临床对照研究[J].肾脏病与透析肾移植杂志,2005,14(6):501-507. 被引量:27

二级参考文献26

  • 1胡伟新,刘春蓓,唐政,俞雨生,王庆文,陈惠萍,刘志红,黎磊石.微型多血管炎肾损害的预后[J].肾脏病与透析肾移植杂志,2004,13(5):419-425. 被引量:11
  • 2Levy JB.New aspects in the management of ANCA positive vasculitis.Nephrol Dial Transplant,2001,16:1314-1317. 被引量:1
  • 3Jayne D,Rasmussen N,Andrassy K,et al.Randomized trial of CTXlophosphamide versus azathioprine as remission maintenance therapy for ANCA-associated vasculitis.N Engl J Med,2003,349:36-44. 被引量:1
  • 4Little MA,Nazar L,Farrington K.Outcome in glomerulonephritis due to systemic small vessel vasculitis:Effect of functional status and non-vasculitic co-morbidity.Nephrol Dial Transplant,2004,19:356-364. 被引量:1
  • 5Hu WX,Liu ZH,Chen HP,et al.Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.Chin Med J,2002,115 (5):705-709. 被引量:1
  • 6Jennette JC,Falk R J,Andrassy K.Nomenclature of systemic vasculitides.Proposal of an international consensus conference.Arthritis Rheum,1994,37:187-192. 被引量:1
  • 7Luqmani RA,Bacon PA,Moots RJ,et al.Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.Q J Med,1994,87:671-678. 被引量:1
  • 8Exley AR,Bacon PA,Luqmani RA,et al.Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.Arthritis Rheum,1997,40:371-380. 被引量:1
  • 9Joy MS,Hogan SL,Jennette JC,et al.A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis.Nephrol Dial Transplant,2005,20 (12):2725-2732. 被引量:1
  • 10Huang YF,Liu ZH,Huang HD,et al.Effects of mycophenolate acid on endothelial cells.International Immunopharmacplogy,2005,5:1029-1039. 被引量:1

共引文献26

同被引文献28

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部